Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + lenvatinib + GEMOX versus placebo + GEMOX as first-line therapy for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma
CTR20222366Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jun 2023; status: active.
02
Drugs
toripalimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20222366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222366.